| abstract |
H:\Interwoven\NRPortbl\DCC\VZS\20339199_I.DOCX-18/06/2020 nAbstract nCompounds are provided having the following structure:() or a pharmaceutically nacceptable salt, tautomer or stereoisomer thereof, wherein Ri, Rb,R2 a, R2B R2 a R3 R 3b nR4 , R4 b,Ri R6, R 7' R 8', R, L L2, a,b,c,d and e are as defined herein. Use ofthe compounds nas a component of lipid nanoparticle formulations for delivery of a therapeutic agent, ncompositions comprising the compounds and methods for their use and preparation are also nprovided. nR N R2 R nR"b R2b R 3b R44 nR 4 N ~R n20000 n--- Compound A n-a- MC3 n-0- Comouwd 5 n-z15000 -4- Compound a n10000 nd n0.0 0,2 GA 0,6 0.8 1.0 12 nmRNA Dose (mg/kg) nFigure 3 |